Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival of myelodysplastic syndrome patients after azacitidine therapy.

BMC cancer - 20 Apr 2026

Thammagul Kanticha, Limpiwakee Suppalux, Chantrathammachart Pichika, Puavilai Teeraya, Chuncharunee Suporn, Niparuck Pimjai

Abstract excerpt

BACKGROUND: Although azacitidine monotherapy improves survival in myelodysplastic (MDS) patients, various outcomes have been found regarding cytogenetic and molecular features. METHODS: This retrospective analysis of 80 Thai patients with MDS treated with azacitidine monotherapy evaluated real-world outcomes in Thailand and identified clinical parameters associated with treatment response and survival....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to DNA-Binding Proteins

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Thailand

Source

Open in PubMed Open full text

Identifiers

PMID: 42010510
DOI: 10.1186/s12885-026-15997-1
PMCID: PMC13231636

Genes

RUNX1
TET2
TF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival of myelodysplastic syndrome patients after azacitidine therapy.PMID 42010510Read ↗

How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments.Semantic proximity Read ↗

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromesSemantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

How I treat higher-risk MDSSemantic proximity Read ↗

Current diagnosis and treatment for myelodysplastc syndromes.Semantic proximity Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Therapy-related myelodysplastic syndrome.Semantic proximity Read ↗

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.